Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neuronyx Inc.

www.neuronyx.com

Latest From Neuronyx Inc.

NewNeural LLC

While there, he found that when human bone marrow cells were treated in a unique way and implanted into an animal brain, the treated cells migrated throughout the brain and differentiated into human neurons. He also found that when these treated cells were implanted into a rodent eye with a damaged retina, the cells migrated to the area of damage and differentiated into new photoreceptor cells. Another discovery by Sugaya identified a small molecule that significantly increased the number of stem cells in the hippocampus and cortex of aged rats.
BioPharmaceutical

Faust Pharmaceuticals

Strasbourg, France-based Faust Pharmaceuticals aims to identify and develop small molecule drug candidates that can modulate the level of neurotransmitters in the brain to treat neurodegenerative disorders including Parkinson's Disease and Alzheimer's Disease.
BioPharmaceutical Europe

Faust Pharmaceuticals

Strasbourg, France-based Faust Pharmaceuticals aims to identify and develop small molecule drug candidates that can modulate the level of neurotransmitters in the brain to treat neurodegenerative disorders including Parkinson's Disease and Alzheimer's Disease.
BioPharmaceutical

Neuronyx Inc.

The time is right to get into the blossoming field of stem cells, believes the high-profile founder of Neuronyx Inc., Hubert Schoemaker, PhD. Fresh from the sale of Centocor, the first-generation biotech that he co-founded, Shoemaker founded Neuronyx in 1999 to develop stem cell-based therapies for neurological disorders.
BioPharmaceutical Regenerative Medicine
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Neuronyx Inc.
  • Senior Management
  • Hubert Schoemaker, PhD, Chmn. & CEO
    Stephen Webster, Pres. & COO
    Tony Ho, MD, SVP, R&D
    George Hobbs, SVP, Corp. Dev.
  • Contact Info
  • Neuronyx Inc.
    Phone: (610) 240-4150
    1 Great Valley Pkwy.
    Ste. 20
    Malvern, PA 19355
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register